Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...

In patients with type 1 diabetes (T1D), sodium-glucose cotransporter 2 (SGLT2) inhibitors plus glucagon receptor antagonists (GRAs) may improve glycemic control, reduce insulin use, and mitigate ...

Please provide your email address to receive an email when new articles are posted on . Last November, at the American College of Rheumatology Convergence 2023, several faculty members presented new ...

As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a] Their primary ...

This risk makes physicians hesitate to initiate SGLT2 inhibitors shortly after a heart attack because information about the safety of this class of medications in this clinical situation is limited.

MADRID — Patients with type 2 diabetes treated with sodium-glucose cotransporter 2 inhibitors (SGLT2is) show significant reductions in the risk of developing neurodegenerative disorders including ...

Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...

SGLT2 inhibitors show significant promise in the treatment of heart failure regardless of how long a patient has had type 2 diabetes, as per a new meta-analysis presented at the European Society of ...

SGLT2 inhibitors curb the action of a protein known as sodium-glucose cotransporter 2, which helps the kidneys reabsorb glucose from the blood. EMPACT-MI is the first analysis to determine if it is ...

Relative to GLP-1RA and DPP-4 inhibitor use, SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not an increased risk for thrombosis in T2D. Among individuals with type 2 ...